Patents by Inventor Anne-Marie Rasmussen

Anne-Marie Rasmussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TELOMERASE POLYPEPTIDE VACCINE FOR TREATING CANCER
    Publication number: 20230277641
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Application
    Filed: December 15, 2022
    Publication date: September 7, 2023
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Telomerase polypeptide vaccine for treating cancer
    Patent number: 11529403
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: December 20, 2022
    Assignee: ULTIMOVACS AS
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Methods and Materials for the Generation of Regulatory T Cells
    Publication number: 20210115401
    Abstract: Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25? T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 22, 2021
    Inventors: Tanja AARVAK, Anne-Marie RASMUSSEN, Gunnar KVALHEIM, Walter Gabriell Borelli PIEDRAS, Anne BRUNSVIG
  • TELOMERASE POLYPEPTIDE VACCINE FOR TREATING CANCER
    Publication number: 20200121771
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 23, 2020
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Telomerase polypeptide vaccine for treating cancer
    Patent number: 10383928
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: August 20, 2019
    Assignee: ULTIMOVACS AS
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • METHODS AND MATERIALS FOR THE GENERATION OF REGULATORY T CELLS
    Publication number: 20190071640
    Abstract: Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25? T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.
    Type: Application
    Filed: August 7, 2018
    Publication date: March 7, 2019
    Inventors: Tanja AARVAK, Anne-Marie RASMUSSEN, Gunnar KVALHEIM, Walter Gabriell Borelli PIEDRAS, Anne BRUNSVIG
  • TELOMERASE POLYPEPTIDE VACCINE FOR TREATING CANCER
    Publication number: 20170232087
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 17, 2017
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • TELOMERASE POLYPEPTIDE VACCINE FOR TREATING CANCER
    Publication number: 20170232088
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 17, 2017
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Telomerase polypeptide vaccine for treating cancer
    Patent number: 9657068
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: May 23, 2017
    Assignee: Ultimovacs AS
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • METHODS AND MATERIALS FOR THE GENERATION OF REGULATORY T CELLS
    Publication number: 20160024470
    Abstract: Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25? T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.
    Type: Application
    Filed: July 22, 2015
    Publication date: January 28, 2016
    Inventors: Tanja AARVAK, Anne-Marie RASMUSSEN, Gunnar KVALHEIM, Walter Gabriell Borelli PIEDRAS, Anne BRUNSVIG
  • Methods and materials for the generation of regulatory T cells
    Patent number: 9119807
    Abstract: Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25? T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: September 1, 2015
    Assignee: Life Technologies AS
    Inventors: Tanja Aarvak, Anne-Marie Rasmussen, Gunnar Kvalheim, Walter Gabriell Borelli Piedras, Anne Brunsvig
  • Polypeptides
    Publication number: 20130129760
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Application
    Filed: February 15, 2011
    Publication date: May 23, 2013
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • METHODS AND MATERIALS FOR THE GENERATION OF REGULATORY T CELLS
    Publication number: 20100129340
    Abstract: Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25? T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.
    Type: Application
    Filed: October 22, 2009
    Publication date: May 27, 2010
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Anne-Marie RASMUSSEN, Tanja Arvak, Gunnar Kvalheim, Walter Gabriell Borelli Piedras, Anne Brunsvig
  • METHODS AND MATERIALS FOR THE GENERATION OF REGULATORY T CELLS
    Publication number: 20100068193
    Abstract: Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25? T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.
    Type: Application
    Filed: February 15, 2007
    Publication date: March 18, 2010
    Applicant: INVITROGEN DYNAL AS
    Inventors: Anne Brunsvig, Anne-Marie Rasmussen, Borelli Piedras, Gunnar Kvalheim, Tanja Aarvak